PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
9.62%
Cash & equivalents growing 9.62% while Biotechnology shows decline of -11.34%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
No Data
No Data available this quarter, please select a different quarter.
9.62%
Below half the Biotechnology median of -9.36% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half the Biotechnology median of -7.14%. Jim Chanos would question if the company faces working capital strain.
-7.18%
PP&E growth ≥ 1.5x the Biotechnology median of -3.75%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.96%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.38%
≥ 1.5x the Biotechnology median of -2.31%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Below half the Biotechnology median of -6.07%. Jim Chanos might see potential stagnation or distress vs. peers.
-5.53%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
6569.50%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-5.06%
1.1-1.25x Biotechnology median of -4.53%. John Neff wonders if liabilities are rising faster than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2126.46%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
No Data
No Data available this quarter, please select a different quarter.
-0.39%
Below half Biotechnology median of -1.94%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-1.27%
Below half Biotechnology median of -4.05%. Joel Greenblatt sees a much lower liability expansion vs. peers.
3.57%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-2.57%
0.5-0.75x Biotechnology median of -4.35%. Guy Spier is cautious about weaker retention vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.56%
Below half Biotechnology median of -7.32%. Jim Chanos suspects slower net worth growth or losses vs. peers.
8.48%
Below half Biotechnology median of -6.07%. Jim Chanos suspects a major slowdown or distress.
0.96%
≥ 1.5x Biotechnology median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-6.20%
Above 1.5x Biotechnology median of -1.48%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-10.07%
Below half of Biotechnology median 13.69%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.